Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.81 |
| ▸ | SHBG | P04278 | 1/20 | 0.81 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.81 |
| ▸ | MAPT | P10636 | 7/20 | 0.71 |
| ▸ | RAB9A | P51151 | 5/20 | 0.71 |
| ▸ | LMNA | P02545 | 4/20 | 0.71 |
| ▸ | NPC1 | O15118 | 3/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.71 |
| ▸ | HTT | P42858 | 2/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.71 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 4/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | HPGD | P15428 | 3/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.66 |
| ▸ | ATM | Q13315 | 1/20 | 0.66 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.66 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29514772 | 1.00 | ESR1 (0.81) | ESR1SHBGESR2MAPTRAB9A | |
| SCHEMBL312243 | 0.90 | ESR1 (1.00) | ESR1SHBGESR2MAPTRAB9A | |
| SCHEMBL30503014 | 0.90 | ESR1 (1.00) | ESR1SHBGESR2MAPTRAB9A | |
| SCHEMBL3584263 | 0.84 | LMNA (0.68) | ESR1SHBGESR2MAPTRAB9A | |
| SCHEMBL9730612 | 0.84 | ESR1 (0.71) | ESR1SHBGESR2MAPTRAB9A | |
| SCHEMBL2331741 | 0.83 | LMNA (1.00) | ESR1SHBGESR2MAPTRAB9A | |
| SCHEMBL22672221 | 0.83 | ESR1 (0.81) | ESR1SHBGESR2MAPTRAB9A | |
| SCHEMBL38652384 | 0.83 | ESR1 (0.81) | ESR1SHBGESR2MAPTRAB9A | |
| SCHEMBL3958571 | 0.83 | LMNA (1.00) | ESR1SHBGESR2MAPTRAB9A | |
| SCHEMBL30204024 | 0.83 | LMNA (1.00) | ESR1SHBGESR2MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022075780-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OVERACTIVE BLADDER | 광주과학기술원 | 2022-04-14 | — | — | WO | disclosed |
| WO-2020231979-A9 | SMALL MOLECULE INHIBITORS OF VIRAL REPLICATION | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2021-06-17 | — | — | WO | disclosed |
| WO-2020231979-A1 | SMALL MOLECULE INHIBITORS OF VIRAL REPLICATION | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2020-11-19 | — | — | WO | disclosed |
| US-7732435-B2 | Chromone derivatives useful as antagonists of VR1 receptors | NOVARTIS AG (CH) | 2010-06-08 | — | — | US | disclosed |
| US-20080312316-A1 | Chromone Derivatives Useful as Antagonists of Vr1 Receptors | CULSHAW ANDREW JAMES | 2008-12-18 | — | — | US | disclosed |
| EP-1963334-A1 | CHROMONE DERIVATIVES USEFUL AS ANTAGONISTS OF VR1 RECEPTORS | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| US-20080114056-A1 | Chromone Derivatives Useful as Vanilloid Antagonists | NOVARTIS AG (CH) | 2008-05-15 | — | — | US | disclosed |
| US-20080114056-A1 | Chromone Derivatives Useful as Vanilloid Antagonists | NOVARTIS AG (CH) | 2008-05-15 | — | — | US | disclosed |
| US-20080114056-A1 | Chromone Derivatives Useful as Vanilloid Antagonists | NOVARTIS AG (CH) | 2008-05-15 | — | — | US | disclosed |
| WO-2007065888-A1 | CHROMONE DERIVATIVES USEFUL AS ANTAGONISTS OF VR1 RECEPTORS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
| EP-1756080-A1 | CHROMONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS | Novartis AG (CH) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005121116-A1 | CHROMONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS | NOVARTIS AG (CH) | 2005-12-22 | — | — | WO | disclosed |
| EP-0171645-B1 | 2H-1-BENZOPYRAN-2-ON DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICINES CONTAINING THESE COMPOUNDS | Roche Diagnostics GmbH (DE) | 1988-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114056-A1 | Chromone Derivatives Useful as Vanilloid Antagonists | TRPV1, CHRM3, TRPV3 | ESR1 923/4885SHBG 3789/4885ESR2 963/4885 |
| US-20080312316-A1 | Chromone Derivatives Useful as Antagonists of Vr1 Receptors | VRK1, VRK2, ARRB1 | ESR1 488/4885SHBG 2719/4885ESR2 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.